Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
NEOG · Nasdaq · United States · In Vitro & In Vivo Diagnostic Substances
In shortNEOGEN CORP is loss-making, generates cash and carries moderate debt, with revenue shrinking (−2.7% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -2.5% | 8/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -0.9% | 16/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -0.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -0.7% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.82× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.38× | 90/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 6.42× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -0.90× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.06 | 24/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 3.7% | 35/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 24.2% | 22/100 |
| Operating margin volatility | 55.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 1.9% | 27/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 527 | 822 | 924 | 895 | 870 |
| Cost of revenue | 284 | 416 | 460 | 473 | 462 |
| Gross profit | 243 | 406 | 464 | 421 | 409 |
| Research & development | 17 | 26 | 23 | 21 | 18 |
| Operating income | 59 | 38 | 59 | (1,061) | (22) |
| Interest expense | – | 27 | 42 | 38 | 24 |
| Pre-tax income | 60 | (22) | (14) | (1,133) | (9) |
| Income tax | 12 | 0.8 | (4.9) | (41) | (1.1) |
| Net income | 48 | (23) | (9.4) | (1,092) | (7.9) |
| Diluted EPS | $0.45 | −$0.12 | −$0.04 | −$5.03 | −$0.04 |
| Diluted shares (millions) | 108 | 189 | 217 | 217 | 218 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
2.06 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Aug 31, 2026 · Data updated Oct 7, 2026